Redwood City, CA, United States of America

Jeffrey Clough

This inventor holds 86 USPTO granted patents and 6 published patent applications, plus 10 CIPO patents and 13 EPO patents, primarily in JAK Inhibition (CPC class C07D498-04). Top assignees: Rigel Pharmaceuticals, Incorporated, Rogel Pharmaceuticals, Inc.. Active years: 2006-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey Clough. Retrieved from https://idiyas.com/inventor/jeffrey-clough

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 86 (Patent Applications = 6)

% Patents Active = 59.3

CIPO Patents = 10 (Patent Applications = 1)

EPO Patents = 13 (Patent Applications = 11)

Average Co-Inventor Count = 8.5

ph-index = 31

Forward Citations = 3,034(Granted Patents)

Forward Citations (Not Self Cited) = 2,316(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Redwood City, CA (US) (2006 - 2023)
Watsonville, CA (US) (2019 - 2023)

Company Filing History:

85 out of 492

Rigel Pharmaceuticals, Incorporated

patents

1 out of 1

Rogel Pharmaceuticals, Inc.

patent

Years Active: 2006-2023

Loading Chart...

Areas of Expertise:

JAK Pathway

Autoimmune Diseases

2,4-Pyrimidinediamine

GDF-8 Inhibitors

Pyrimidine-2-Amine

Kinase Inhibitors

Therapeutics

Compositions

Methods

86 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11827628 - Compositions and methods for inhibition of the JAK pathway (2023-11-28),

2. 11667611 - Compositions and methods for inhibition of the JAK pathway (2023-06-06),

3. 11230554 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds (2022-01-25),

4. 11198689 - Compositions and methods for inhibition of the JAK pathway (2021-12-14),

5. 11021468 - TGF-ß inhibitors (2021-06-01),

6. 11007193 - 2,4-pyrimidinediamine compounds and their uses (2021-05-18),

7. 10828301 - 2,4-pyrimidinediamine compounds and their uses (2020-11-10),

8. 10709703 - 2,4-pyrimidinediamine compounds and their uses (2020-07-14),

9. 10682350 - 2,4-pyrimidinediamine compounds and their uses (2020-06-16),

10. 10421752 - Compositions and methods for inhibition of the JAK pathway (2019-09-24),

11. 10369148 - 2,4-pyrimidinediamine compounds and their uses (2019-08-06),

12. 10314840 - 2,4-pyrimidinediamine compounds and their uses (2019-06-11),

13. 10259826 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds (2019-04-16),

14. 9913842 - 2,4-pyrimidinediamine compounds and their uses (2018-03-13),

15. 9878992 - GDF-8 inhibitors (2018-01-30),

Title: The Innovative Journey of Jeffrey Clough: Pioneering the Future of Biomedical Sciences.

Introduction: Jeffrey Clough, a prolific inventor based in Redwood City, CA, is a visionary in the field of biomedical sciences. With an impressive portfolio of 86 patents, Clough has revolutionized the industry with his groundbreaking discoveries and inventions.

Latest Patents: Among his latest patents is the groundbreaking invention titled "Compositions and methods for inhibition of the JAK pathway." These compounds hold the key to treating various conditions by modulating the JAK pathway and inhibiting JAK kinases, particularly JAK3. The formulas I-V have paved the way for innovative treatment strategies in the realm of biomedicine.

Career Highlights: Clough's remarkable career has seen him make significant contributions to companies like Rigel Pharmaceuticals, Incorporated, and Rogel Pharmaceuticals, Inc. His expertise and innovative spirit have been instrumental in driving these organizations towards success in the highly competitive biomedical landscape.

Collaborations: Throughout his career, Clough has collaborated with esteemed peers such as Rajinder Paul Singh and Somasekhar Bhamidipati. Together, they have spearheaded groundbreaking research initiatives and have played a vital role in shaping the future of biomedical innovation.

Conclusion: Jeffrey Clough's relentless dedication to innovation and his pioneering spirit have cemented his position as a trailblazer in the field of biomedical sciences. With a string of patents to his name and a legacy of groundbreaking inventions, Clough continues to inspire the next generation of inventors and researchers in their quest to push the boundaries of scientific discovery.

Profile summary based on public USPTO records.